Tayside drugs specialist inks Sanofi partnership
Dundee-based Exscientia has struck a drug discovery partnership with global pharma company Sanofi that could generate substantial financial returns.
The Scots firm, which is at the forefront of artificial intelligence-driven drug discovery, said the research collaboration and licence option agreement with Sanofi was focused on the area of metabolic disease.
Exscientia will receive ongoing research funding and could receive up to €250 million (£210m) in success-based payments if certain development milestones are achieved.
Chief executive Andrew Hopkins said: “Sanofi has put together an excellent experimental backbone for this collaboration and we look forward to delivering high-value projects for the company.”
Any licensed products reaching the market will qualify for recurrent sales milestones.